Pancreatic Cancer Research

ResearcherFox Chase Cancer CenterActive in the last 2 years

Joshua E. Meyer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7585-5738; OpenAlex author ID A5052704200. Sources: ClinicalTrials.gov.

Their work

Papers
16 (first author 1, last author 5)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2013: 1 trial · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 1 trial · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers, 1 trial

Papers 16

  1. Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer. Co-author DOI 10.1007/s12029-025-01188-x↗
  2. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. Co-author DOI 10.1089/jpm.2024.0313↗
  3. Pulsed low-dose-rate radiation (PLDR) reduces the tumor-promoting responses induced by conventional chemoradiation in pancreatic cancer-associated fibroblasts Co-author DOI 10.1101/2024.01.13.575510↗
  4. The Role of Dose Escalation in Pancreatic Cancer: Go Big or Go Home? Co-author DOI 10.1016/j.ijrobp.2022.09.050↗
  5. Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-021-10219-3↗
  6. ASO Author Reflections: Neoadjuvant Chemoradiation Impacts the Prognostic Effect of Surgical Margin Status in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-021-10230-8↗
  7. Predicting positive peritoneal cytology in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03471-9↗
  8. Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? Co-author DOI 10.5306/wjco.v12.i2.54↗
  9. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1634/theoncologist.2019-0562↗
  10. Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis. Last author DOI 10.1097/coc.0000000000000472↗
  11. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000227↗
  12. Dosimetric predictors of hematologic toxicity in patients undergoing concurrent gemcitabine-based chemoradiation for localized pancreatic cancer. Last author DOI 10.1016/j.prro.2015.11.005↗
  13. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Last author DOI 10.1016/j.prro.2015.04.004↗
  14. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advan… First author DOI 10.1016/j.radonc.2014.08.014↗
  15. Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. Co-author DOI 10.1111/hpb.12058↗
  16. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery ma… Co-author DOI 10.1245/s10434-013-3396-5↗

Trials 3

  1. Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer Principal investigator NCT06984562↗
  2. Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source Principal investigator NCT02843945↗
  3. Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Principal investigator NCT01739439↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sanjay S. Reddy · 6 shared papers, 2021–2025 · strength 1.25
  2. Efrat Dotan · 4 shared papers, 2021–2025 · strength 0.73
  3. John Parker Hoffman · 7 shared papers, 2014–2022 · strength 0.54
  4. Steven J. Cohen · 7 shared papers, 2014–2022 · strength 0.49
  5. Shannon M. Lynch · 2 shared papers, 2025 · strength 0.44
  6. Edna Cukierman · 2 shared papers, 2024–2025 · strength 0.42
  7. Jordan R. Kharofa · 1 shared paper, 2023 · strength 0.39
  8. Talha Shaikh · 4 shared papers, 2015–2022 · strength 0.36
  9. Jenny A. O'Brien · 1 shared paper, 2025 · strength 0.23
  10. Michael J. Hall · 2 shared papers, 2014–2021 · strength 0.23
  11. Lora S. Wang · 3 shared papers, 2015–2018 · strength 0.22
  12. Kristopher S. Raghavan · 1 shared paper, 2024 · strength 0.21
  13. Debora Barbosa Vendramini Costa · 1 shared paper, 2024 · strength 0.21
  14. Tiffany Luong · 1 shared paper, 2024 · strength 0.21
  15. Ralph A. Francescone III · 1 shared paper, 2024 · strength 0.21
  16. Janusz Franco‐Barraza · 1 shared paper, 2024 · strength 0.21
  17. Namrata Vijayvergia · 1 shared paper, 2025 · strength 0.21
  18. Lauren Laderman · 1 shared paper, 2025 · strength 0.21
  19. Anush Narasimhan Sridharan · 1 shared paper, 2025 · strength 0.21
  20. Igor A. Astsaturov · 1 shared paper, 2025 · strength 0.21
  21. Maitham A. Moslim · 1 shared paper, 2021 · strength 0.19
  22. Eileen A. O’Halloran · 1 shared paper, 2021 · strength 0.15
  23. Eddie Zhang · 1 shared paper, 2022 · strength 0.15
  24. Nicholas George Zaorsky · 1 shared paper, 2019 · strength 0.14
  25. William F. Regine · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.